CellCure Neurosciences
Cell Therapies for Neural Degenerative Diseases
StartupCellCure Neurosciences is a Jerusalem-based startup in the Health Tech & Life Sciences sector, established in 2005. Cell Therapies for Neural Degenerative Diseases. The company has raised a total of $21.79M across 9 funding rounds, currently at the Seed stage. Key investors include BioTime Inc., Hadasit Bio-Holdings, Teva Pharmaceuticals. The company has 11-50 employees. Core technologies: Biologicals, Cells.
With $21.79M in total funding, CellCure Neurosciences is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2C business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageSeed
- ProductClinical Trial
- ModelB2C
- Employees11-50
- HQJerusalem
- DistrictJerusalem District
- Last Round$2.5M
- BioTime Inc.
- Hadasit Bio-Holdings
- Teva Pharmaceuticals
7 articles covered by sources including www.businesswire.com,
en.globes.co.il,
www.globes.co.il.
What does CellCure Neurosciences do?
Cell Cure Neurosciences is a biotechnology company developing cell therapies based on the use of human embryonic stem cells for the treatment of retinal and neural degenerative diseases. The company uses these powerful stem cells to manufacture the retinal pigment epithelial (RPE) cell. Cell Cure’s first product in development, OpRegen, contains hESC-derived RPE cells to treat age-related macular degeneration (AMD). OpRegen is being developed as a frontline therapy for the dry form of AMD, which affects approximately 90% of AMD patients. Cell Cure is currently conducting a phase 1/2 clinical trial of OpRegen to treat the larger market of dry AMD, for which there is currently no FDA-approved therapeutic. The company has recently completed construction of a cGMP manufacturing facility for the production of OpRegen and other cell therapy products. Cell Cure Neurosciences is a fully owned subsidiary of California-based Lineage Cell Therapeutics, formerly BioTime.
How much funding has CellCure Neurosciences raised?
CellCure Neurosciences has raised $21.79M in total funding across 9 rounds. The company is currently at the Seed stage. Key investors include BioTime Inc., Hadasit Bio-Holdings, Teva Pharmaceuticals.
What sector is CellCure Neurosciences in?
CellCure Neurosciences operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Biomaterials & Tissue Engineering, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals, Healthcare.
Where is CellCure Neurosciences located?
CellCure Neurosciences is based in Hadassah Ein Kerem, Jerusalem, Israel, Jerusalem District.